全球免疫肿瘤精准医学市场（2023-2030）：最终用户、癌症类型、治疗类型和生物标誌物的规模、份额、增长分析和预测

全球免疫肿瘤精准医疗市场规模预计将从2021年的494亿美元增长到2022年的547.4亿美元，预测期内年复合成长率为10.8%，到2030年将达到1243.3亿美元。 。

全球癌症免疫精准医学是癌症治疗中一个先进且有前景的领域，利用精准和个性化的方法来靶向和根除癌细胞。这种创新方法将免疫疗法和精准医学相结合，旨在提高癌症治疗的疗效，同时最大限度地减少副作用。新一代测序和生物标誌物分析等尖端技术在识别特定肿瘤特征和指导治疗决策方面发挥着重要作用。随着持续的研究和临床试验，免疫肿瘤学精准医学具有巨大的潜力，可以彻底改变癌症治疗并改善全世界患者的治疗结果。

癌症患病率的不断上升预计将推动对免疫肿瘤学精准医疗的需求。随着癌症患者数量的持续增长，人们越来越需要更有效、更有针对性的治疗方案。癌症免疫精准医学提供了根据特定肿瘤特征和免疫反应为个体患者量身定制癌症治疗的可能性。利用免疫系统的力量来对抗癌症，这一新兴领域有望改善治疗结果并应对不同类型癌症带来的挑战。

免疫肿瘤学越来越多地使用联合疗法与传统癌症治疗（例如化疗和放疗）一起使用。这种方法因其提高治疗效果和对抗治疗耐药性的潜力而受到欢迎。例如，免疫疗法和化疗的结合在治疗某些癌症类型（例如肺癌和黑色素瘤）方面显示出有希望的结果。化疗可以缩小肿瘤，但免疫疗法可以帮助患者的免疫系统识别癌细胞并更有效地攻击它们。

在本报告中，我们研究了全球癌症免疫精准医学市场，提供了市场概况，分析了市场的各种影响因素、技术和创新趋势、监管环境、市场规模的转变和预测以及各个细分市场及地区、细分、竞争格局、主要企业概况等。

目录

执行摘要

调查方法

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

关键市场洞察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 知识产权分析
• 贸易分析
• 启动分析
• 原材料分析
• 创新矩阵
• 管道产品分析
• 宏观经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及预测

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管状况
• 波特的分析
• Skyquest 对未来颠覆的特别见解

全球免疫肿瘤精准医学市场（按最终用户）

• 市场概况
• 医院
• 诊所
• 研究所/其他

全球免疫肿瘤学精准医学市场，按癌症类型划分

• 市场概况
• 肺癌
• 乳腺癌
• 前列腺癌
• 黑色素瘤/其他

全球免疫肿瘤学精准医学市场，按治疗类型

• 市场概况
• 检查点抑製剂
• CAR-T细胞疗法
• 癌症疫苗
• 其他的

全球免疫肿瘤学精准医学市场：按生物标誌物分类

• 市场概况
• PD-L1
• BRCA
• KRAS
• EGFR
• 其他的

全球免疫肿瘤精准医学市场（按地区）

• 市场概况
• 北美
• 欧洲
• 亚太地区
• 拉美
• 中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位
• 各大公司的招聘策略
• 关键成功策略
• 近期市场活动
• 主要参与者的市场份额

主要公司简介

• Adaptimmune Therapeutics plc
• Agenus Inc.
• Amgen Inc.
• AstraZeneca plc
• Bristol Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Iovance Biotherapeutics, Inc.
• Juno Therapeutics, Inc.
• Kite Pharma, Inc.
• Merck &Co., Inc.
• Neon Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Seattle Genetics, Inc.
• Takeda Pharmaceutical Company Limited

Market Insights

Global Precision Immuno-Oncology Market size was valued at USD 49.4 billion in 2021 and is poised to grow from USD 54.74 billion in 2022 to USD 124.33 billion by 2030, growing at a CAGR of 10.8% in the forecast period (2023-2030).

Global Precision Immuno-Oncology is an advanced and promising field in cancer treatment, utilizing precise and personalized approaches to target and eradicate cancer cells. By combining immunotherapy with precision medicine, this innovative approach aims to enhance the effectiveness of cancer treatment while minimizing side effects. Cutting-edge technologies, such as next-generation sequencing and biomarker analysis, play a crucial role in identifying specific tumor characteristics and guiding treatment decisions. With ongoing research and clinical trials, Precision Immuno-Oncology holds great potential in revolutionizing cancer care and improving patient outcomes worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Immuno-Oncology Market Segmental Analysis

Precision Immuno-Oncology Market is segmented on the basis of Treatment type, cancer type, end-user, biomarker, and region. By end use, the Precision Immuno-Oncology Market is segmented into hospitals, clinics, research institutes, and others. By cancer type, the Precision Immuno-Oncology Market is segmented into Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others. By treatment type, the Precision Immuno-Oncology Market is segmented into immune checkpoint inhibitors, car T cell therapy, cancer vaccines, and others. By biomarker, the Precision Immuno-Oncology Market is segmented into PD-L1, BRCA, KRAS, EGFR, and others. By region, the Precision Immuno-Oncology Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver

The increasing prevalence of cancer is expected to drive the demand for Precision Immuno-Oncology. As cancer cases continue to rise, there is a growing need for more effective and targeted treatment options. Precision Immuno-Oncology offers the potential to tailor cancer therapies to individual patients based on their specific tumor characteristics and immune responses. By harnessing the power of the immune system to fight cancer, this emerging field holds promise in improving treatment outcomes and addressing the challenges posed by various types of cancer.

Restraints

The growth of the Global Precision Immuno-Oncology market is impeded by the significant cost associated with its implementation. The advanced technologies and personalized nature of precision immuno-oncology therapies can be financially challenging for both healthcare providers and patients. The high cost of treatments may limit accessibility and adoption, hindering the market's potential growth. Addressing these cost-related challenges through research, development, and innovative pricing strategies will be crucial to overcome this restraint and unlock the full potential of precision immuno-oncology in cancer treatment.

Market Trends

In precision immuno-oncology treatments is the increasing utilization of combination therapies alongside traditional cancer treatments like chemotherapy and radiation therapy. This approach has gained popularity due to its potential to enhance treatment effectiveness and combat treatment resistance. For instance, the combination of immunotherapy and chemotherapy has shown promising outcomes in treating certain cancer types like lung cancer and melanoma. While chemotherapy reduces tumor size, immunotherapy helps the patient's immune system recognize and attack cancer cells more effectively.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Precision Immuno-Oncology Market by End use

• Market Overview
• Hospital
• Clinics
• research institutes and others

Global Precision Immuno-Oncology Market by Cancer type

• Market Overview
• Lung cancer
• breast cancer
• prostate cancer
• melanoma and others

Global Precision Immuno-Oncology Market by Treatment type

• Market Overview
• checkpoint inhibitors
• car T cell therapy
• cancer vaccines
• and others

Global Precision Immuno-Oncology Market by Biomarker

• Market Overview
• PD-L1
• BRCA
• KRAS
• EGFR
• and others.

Global Precision Immuno-Oncology Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Adaptimmune Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iovance Biotherapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Juno Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kite Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neon Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seattle Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments